

Portland State University

**PDXScholar**

---

OHSU-PSU School of Public Health Faculty  
Publications and Presentations

OHSU-PSU School of Public Health

---

2018

# Diagnostic Performance of Blood Inflammatory Markers for Tuberculosis Screening in People Living with HIV

Katherine Farr

*University of California San Francisco*

Resmi Ravindran

*University of California at Davis*

Luke Strnad

*OHSU-PSU School of Public Health*

Emily Chang

*University of California San Francisco*

Leah H. Chaisson

*Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland*

Follow this and additional works at: [https://pdxscholar.library.pdx.edu/sph\\_facpub](https://pdxscholar.library.pdx.edu/sph_facpub)



See next page for additional authors  
Part of the [Community Health Commons](#), and the [Virus Diseases Commons](#)

**Let us know how access to this document benefits you.**

---

## Citation Details

Farr, K., Ravindran, R., Strnad, L., Chang, E., Chaisson, L. H., Yoon, C., ... & Byanyima, P. (2018). Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV. *PLoS one*, 13(10), e0206119.

This Article is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School of Public Health Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [pdxscholar@pdx.edu](mailto:pdxscholar@pdx.edu).

---


**Authors**

Katherine Farr, Resmi Ravindran, Luke Strnad, Emily Chang, Leah H. Chaisson, Christina Yoon, William Worodria, Alfred Andama, Irene Ayakaka, Priscilla Bbosa Nalwanga, and multiple additional authors

RESEARCH ARTICLE

# Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV

Katherine Farr<sup>1,2</sup>, Resmi Ravindran<sup>3</sup>, Luke Strnad<sup>4,5</sup>, Emily Chang<sup>1,6</sup>, Lelia H. Chaisson<sup>7</sup>, Christina Yoon<sup>1</sup>, William Worodria<sup>8,9</sup>, Alfred Andama<sup>10,11</sup>, Irene Ayakaka<sup>11,12</sup>, Priscilla Bbosa Nalwanga<sup>11</sup>, Patrick Byanyima<sup>11</sup>, Nelson Kalema<sup>13</sup>, Sylvia Kaswabuli<sup>11</sup>, Wincelous Katagira<sup>11</sup>, Kyomugisha Denise Aman<sup>11</sup>, Emmanuel Musisi<sup>11,14</sup>, Nuwagaba Wallen Tumwine<sup>11</sup>, Ingvar Sanyu<sup>11</sup>, Robert Ssebunya<sup>11</sup>, J. Lucian Davis<sup>15,16</sup>, Laurence Huang<sup>1,6</sup>, Imran H. Khan<sup>3\*</sup>, Adithya Cattamanchi<sup>1,2</sup>



**1** Division of Pulmonary and Critical Care Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, California, United States of America, **2** Curry International Tuberculosis Center, University of California San Francisco, San Francisco, California, United States of America, **3** Department of Pathology and Laboratory Medicine, University of California at Davis, Sacramento, California, United States of America, **4** Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, United States of America, **5** Epidemiology Programs, Oregon Health & Science University-Portland State University School of Public Health, Portland, Oregon, United States of America, **6** Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, California, United States of America, **7** Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, **8** Department of Medicine, School of Medicine, Makerere University, Kampala, Uganda, **9** Division of Respiratory Medicine, Department of Medicine, Mulago Hospital, Kampala, Uganda, **10** Department of Medicine, Mulago Hospital, Makerere University, Kampala, Uganda, **11** Infectious Diseases Research Collaboration, Kampala, Uganda, **12** International Multidisciplinary Programme to Address Lung Health and TB in Africa, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, **13** Infectious Diseases Institute, Department of Research, Makerere College Health Sciences, Makerere University, Kampala, Uganda, **14** Department of Biochemistry, College of Natural Sciences, Makerere University, Kampala, Uganda, **15** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America, **16** Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America

**OPEN ACCESS**

**Citation:** Farr K, Ravindran R, Strnad L, Chang E, Chaisson LH, Yoon C, et al. (2018) Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV. PLoS ONE 13(10): e0206119. <https://doi.org/10.1371/journal.pone.0206119>

**Editor:** Juraj Ivanyi, King's College London, UNITED KINGDOM

**Received:** December 6, 2017

**Accepted:** October 8, 2018

**Published:** October 23, 2018

**Copyright:** © 2018 Farr et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data for this study are freely available from the UCSF MIND Study. Individuals interested in the data may contact the MIND Steering Committee and data will be released after reviewing that the intended use is consistent with study goals and that persons requesting the data have appropriate human subjects research training and approvals, if needed. Dr. Abdul Sessolo ([Asessolo@idrc-uganda.org](mailto:Asessolo@idrc-uganda.org)) is the focal point for the MIND Steering Committee.

☞ These authors contributed equally to this work.  
\* [ihkhan@ucdavis.edu](mailto:ihkhan@ucdavis.edu)

## Abstract

### Background

Approaches to screening for active tuberculosis (TB) among people living with HIV are inadequate, leading to missed diagnoses and poor implementation of preventive therapy.

### Methods

Consecutive HIV-infected adults hospitalized at Mulago Hospital (Kampala, Uganda) between June 2011 and July 2013 with a cough  $\geq 2$  weeks were enrolled. Patients underwent extensive evaluation for pulmonary TB. Concentrations of 43 cytokines/chemokines were measured at the same time point as C-reactive protein (CRP) in banked plasma samples using commercially-available multiplex kits. Advanced classification algorithms were used to rank cytokines/chemokines for their ability to identify TB, and to model the specificity

**Funding:** LS was supported by a training grant from the National Institutes of Health (5T32AI007641-12, <https://www.nih.gov/>). LHC was supported by a training grant from the National Institutes of Health (5T32AI102623, <https://www.nih.gov/>). JLD was supported by a grant from the National Institutes of Health (K23AI080147, <https://www.nih.gov/>). Patient enrollment and specimen collection was supported by grants from National Institutes of Health/ National Heart, Lung, and Blood Institute to LH (K24HL087713 and R01HL090335, <https://www.nih.gov/>), and this sub-study was supported by a Pilot Award to AC from the National Institutes of Health/ National Institute of Allergy and Infectious Diseases-funded UCSF Center for AIDS Research (P30-AI027763, <http://cfar.ucsf.edu/>).

**Competing interests:** The authors have declared that no competing interests exist.

of the top-ranked cytokines/chemokines individually and in combination with sensitivity constrained to  $\geq 90\%$  as recommended for TB screening.

## Results

The median plasma level of 5 biomarkers (IL-6, INF- $\gamma$ , MIG, CRP, IL-18) was significantly different between patients with and without TB. With sensitivity constrained to 90%, all had low specificity with IL-6 showing the highest specificity (44%; 95% CI 37.4–49.5). Biomarker panels were found to be more valuable than any biomarker alone. A panel combining INF- $\gamma$  and IL-6 had the highest specificity (50%; 95% CI 46.7–53.3). Sensitivity remained high (>85%) for all panels among sputum smear-negative TB patients.

## Conclusions

Direct measurement of unstimulated plasma cytokines/chemokines in peripheral blood is a promising approach to TB screening. Cytokine/chemokine panels retained high sensitivity for smear-negative TB and achieved improved specificity compared to individual cytokines/chemokines. These markers should be further evaluated in outpatient settings where most TB screening occurs and where other illnesses associated with systematic inflammation are less common.

## Introduction

Tuberculosis (TB) now ranks as the most common infectious disease cause of death and accounts for approximately one third of all deaths in people living with HIV (PLHIV) [1, 2]. To combat this deadly co-infection, the World Health Organization (WHO) articulated the "3 I's" strategy for reducing the burden of TB among PLHIV [3]. Key parts of this strategy include intensified case finding (ICF) consisting of screening all PLHIV for active TB at every health-care encounter, followed by isoniazid preventative therapy (IPT) for those who screen negative and diagnostic testing for those who screen positive [4, 5]. However, the uptake and efficiency of IPT and ICF are limited by the lack of a TB screening test that has high enough sensitivity to rule-out TB for patients who test negative—thereby facilitating IPT initiation—and moderate specificity to identify a smaller subset of patients who require confirmatory TB diagnostic testing, thereby facilitating ICF.

Currently, the WHO recommends TB screening be performed using a four-part symptom screen alone or in conjunction with chest radiography (CXR) for PLHIV in high burden settings [5, 6]. Although the symptom screen has high sensitivity, recent data indicate that nearly all PLHIV are symptom screen-positive, particularly in sub-Saharan Africa [6–14]. The addition of CXR improves specificity, but cost and infrastructure requirements make implementation difficult at many HIV/AIDS clinics [6, 11, 14–16]. Thus, TB screening currently results in few PLHIV being identified as candidates for IPT and the vast majority requiring confirmatory testing. For these reasons, a low-cost and accurate screening test that can be performed by front-line health workers has been ranked among the highest priority needs for TB diagnostics [17, 18].

Measurement of inflammatory markers, cytokines and chemokines holds promise for facilitating TB screening [19, 20]. Previous studies have analyzed the accuracy of individual inflammatory markers such as C-reactive protein (CRP) and cytokines/chemokines such as interferon gamma (INF- $\gamma$ ), interferon gamma-induced protein (IP-10), monokine induced by

interferon- $\gamma$  (MIG), interleukin 6 (IL-6), and interleukin 18 (IL-18) for diagnosing active TB [21–27]. Of these, CRP has shown the most promise as a potential TB screening tool with high (89%) sensitivity for active TB and variable specificity (generally higher among outpatients and lower among hospitalized patients) [10, 22, 28–31]. We hypothesized that a panel of inflammatory markers, cytokines and/or chemokines measured directly in blood samples would have higher diagnostic accuracy for TB than CRP alone. To test this hypothesis, we measured levels of CRP and 43 cytokines/chemokines in stored plasma samples from an inpatient cohort of HIV-infected adults with presumptive pulmonary TB.

## Methods

### Study population and setting

We analyzed stored plasma samples from consecutive HIV-infected adults enrolled between June 2011 and July 2013 in an ongoing study, the International HIV-associated Opportunistic Pneumonias (IHOP) Study, of patients admitted to Mulago Hospital in Kampala, Uganda with cough for  $\geq 2$  weeks. Mulago Hospital is the national referral hospital in Uganda. As part of the parent study, patients submitted two sputum samples for acid-fast bacilli (AFB) smear microscopy (LED fluorescence microscopy) and liquid mycobacterial culture (MGIT), and one sample for GeneXpert MTB/RIF testing [32, 33]. Patients were followed-up two months after enrollment to assess for clinical improvement and repeat microbiologic assessment for TB if symptoms had not improved. Blood samples were collected in EDTA anti-coagulant at the time of enrollment and plasma was stored at  $-80$  degrees Celsius. For this study, we included consecutive HIV-infected adult patients who 1) did not have a prior history of TB; 2) had sufficient sputum culture results to assess the reference standard (see Outcome Definition below); and 3) had a stored plasma sample available for analysis. The parent study (IHOP) was approved by institutional review boards at the University of California San Francisco and Makerere University, and by the Uganda National Council for Science and Technology. Informed written consent was obtained for participants at the time of their original enrollment as part of the IHOP studies. As this study represents a secondary analysis from that cohort, additional informed consent was not required. All data and samples were obtained and stored according to protocols approved by the Committee on Human Research at the University of California San Francisco, the School of Medicine Research Ethics Committee at Makerere University (Kampala, Uganda), and the Uganda National Council for Science and Technology.

### Multiplex cytokine/chemokine analysis

Two separate multiplex panels were used to measure a total of 43 cytokines/chemokines in plasma samples from 74 patients that had undergone only a single freeze-thaw cycle to minimize degradation. Samples were stored for approximately three years at  $-70$  C prior to analysis. One kit included 41 cytokines/chemokines (EMD Millipore, Billerica, MA): Soluble CD40 ligand (sCD40L), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)- $\alpha$ , TNF- $\beta$ , transforming growth factor (TGF)- $\alpha$ , chemokine ligand 5/RANTES (CCL5), platelet-derived growth factor (PDGF)-AB/BB, PDGF-AA, macrophage inflammatory protein (MIP)-1 $\beta$ , MIP-1 $\alpha$ , macrophage-derived chemokine (MDC), monocyte chemotactic protein (MCP)-1, MCP-3, interleukin (IL)-17, IL-15, IL-13, IL-12 (p70), IL-12 (p40), IL-10, IL-9, IL-8, IL-7, IL-6, IL-5, IL-4, IL-3, IL-2, IL-1ra, IL-1 $\beta$ , IL-1 $\alpha$ , IFN- $\gamma$ , IFN- $\alpha$ 2, IP-10, growth-related oncogene (GRO), granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), fractalkine, Fms-related tyrosine kinase 3 (Flt-3) ligand, fibroblast growth factor (FGF)-2, eotaxin, and epidermal growth factor (EGF). The second kit (Bio-Rad, Hercules, CA) included 2 cytokines/chemokines: monokine induced by interferon- $\gamma$

(MIG) and IL-18 [21]. Based on initial results (See [Results](#): Biomarker Selection), 6 cytokines/chemokines were selected for further evaluation in 262 patients using custom-ordered multiplex kits: IFN- $\gamma$ , IL-6, GRO, MDC (EMD Millipore, Billerica, MA), and IL-18 and MIG (Bio-Rad, Hercules, CA). The multiplex analysis was performed in duplicate on all samples according to the manufacturer's recommendations at the Center for Comparative Medicine Laboratory, University of California, Davis. In addition to cytokines/chemokines levels (pg/ml), CRP levels (mg/L) were measured on a second aliquot of plasma in the Zuckerberg San Francisco General Hospital (ZSFG) Chemistry Laboratory by a turbidimetric method using a Beckman Coulter Analyzer. Technicians measuring cytokine/chemokine levels and CRP levels were blinded to clinical data including TB status. Patients were excluded from the data analysis if there was insufficient plasma to perform CRP measurement, results of duplicate biomarker measurements were not available, or the coefficient of variation was  $>0.3$  between duplicate measurements.

### Outcome definition


We classified patients as having TB if sputum mycobacterial culture results were positive and speciation testing confirmed *Mycobacterium tuberculosis* complex, or if culture results were negative but both AFB smear and GeneXpert MTB/RIF results were positive. We classified patients as not having TB if all microbiologic testing for TB—including at least two liquid culture results—was negative and patients either had clinical improvement without anti-TB therapy or an alternate diagnosis established by the 2-month follow-up visit.

### Data analysis

We compared the differences in median biomarker responses between TB and non-TB patients using the Mann-Whitney test. We performed random forest modeling using two-thirds of the dataset to rank the relative variable importance of each biomarker in differentiating between TB and non-TB patients based on a mean decrease in Gini impurity index, a measure of heterogeneity in a group. A greater decrease in Gini impurity index indicates better classification, thus indicating a biomarker has greater relative importance [34, 35]. We subsequently built biomarker panels starting with the two top-ranked biomarkers based on variable importance and including the next highest ranked biomarker one at a time. For each panel, we developed a prediction algorithm for identifying TB using SuperLearner, a machine-learning ensemble that compares different learners (prediction methods) using cross-validated risk [36, 37]. SuperLearner builds a weighted linear combination of the included learners favoring those that minimize mean squared error to return predictions on the dataset using cross-validation to prevent overfitting. For this analysis, we included logistic regression, Bayes' generalized linear models, lasso, random forest, and a null model (in order to assess relative performance with other methods) as candidate learners [38–40]. After fitting the SuperLearner algorithm with two-thirds of the dataset, we applied it to the entire dataset and used the predicted probabilities of TB obtained after 10-fold cross-validation to calculate sensitivity, specificity, and cross-validated area under the curve (AUC), along with associated 95% confidence intervals (CI). For all biomarker panels, we constrained sensitivity to be 90% or higher based on the WHO's target product profile for a TB screening test [7]. All analyses were performed using R, version 3.0.2.

### Results

Of 865 patients enrolled in the parent study, 306 (35%) did not have a definite TB status, 111 (13%) had prior TB, and 10 (1%) had no stored sample. Data from the first 74 eligible patients (66% of whom were culture-positive for TB) were used for biomarker selection only. Of the



**Fig 1. Patient selection.** Of 865 patients enrolled in the parent study, 427 (49%) did not meet eligibility criteria, and 74 (9%) were included only for biomarker selection. Of the 364 patients eligible for the full study, 102 (28%) were excluded from the analysis. Abbreviations: TB, tuberculosis; CRP, C-reactive protein.

<https://doi.org/10.1371/journal.pone.0206119.g001>

remaining 364 patients, 9 (2%) showed a coefficient of variation  $>0.3$  for at least one cytokine/chemokine, while 93 (25%) did not have CRP testing performed (Fig 1). Thus, 262 patients were included in the main analysis. Among the 262 patients, 150 (57%) were female, median age was 34 years (IQR 29–39), median CD4 count was 86 cells/ $\mu\text{L}$  (IQR 24–257), 65 (25%) were on anti-retroviral therapy, and 43% had advanced illness confining them to bed rest for at least part of each day. Of the included participants, 155 (59%) had culture-positive TB (68% smear-positive and 32% smear-negative) and 107 (41%) were assessed to be TB-negative based on microbiological evaluation and clinical follow-up. Of note, there were no significant differences in clinical or demographic characteristics among patients included and excluded from the analysis (data not shown).

### Biomarker selection (N = 74)

The median level (pg/ml) of 13 of 43 cytokines/chemokines measured was significantly different between patients with (n = 49) and without (n = 25) TB (S1 Table). The median level of CRP was also significantly higher in TB patients compared to patients without TB. Median



levels were  $\geq 2$ -fold higher among patients with TB than patients without TB for INF- $\gamma$ , MIG, IL-6, IL-18, and G-CSF and were  $\geq 1.5$ -fold higher for CRP, IL-8, IP-10, GRO, SCD-40L, TNF- $\alpha$ , and IL-1 $\alpha$ . Results were similar when biomarkers were considered together and ranked by variable importance (S2 Table). The median level of 6 of the top 10 biomarkers based on variable importance (INF- $\gamma$ , IL-18, CRP, IL-6, GRO, IP-10) was  $\geq 1.5$ -fold higher among patients with TB than patients without TB. Two of the biomarkers (MDC and IL-17) had levels that were lower among patients with TB than patients without TB.

We selected the top 7 biomarkers (INF- $\gamma$ , IL-18, CRP, IL-6, MDC, GRO, and IP-10) identified as promising based on variable importance for further analysis based on feasibility considerations. However, we replaced IP-10 with MIG for further analysis despite a lower variable importance score because of the  $\geq 2$ -fold difference in the medial level of MIG between patients with and without TB, prior data demonstrating that MIG and IP-10 levels were highly correlated, and prior data suggesting that IP-10 is more likely to degrade after long-term storage [21, 41].

### Diagnostic accuracy (N = 262)

Among the remaining 262 patients, the median plasma level of 5 of the 7 selected biomarkers (IL-6, INF- $\gamma$ , MIG, CRP, IL-18) was significantly different between patients with and without TB (Table 1). Median levels were  $\geq 3$ -fold higher among TB patients for IL-6 and INF- $\gamma$ ,  $\geq 2$ -fold higher for MIG and CRP, and 1.9-fold higher for IL-18. When considered together, the rank order from highest to lowest based on variable importance was IFN- $\gamma$ , IL-6, MIG, IL-18, CRP, MDC, and GRO (Table 1).

With sensitivity constrained to be at least 90%, all 7 individual biomarkers had low specificity for active TB (S3 Table). IL-6 had the highest specificity (44%, 95% CI 37.4–49.5). In the assessment of biomarker panels, with sensitivity constrained to 90%, specificity was higher with the combination of IFN- $\gamma$  and IL-6 (50%, 95% (CI 46.7–53.3) than for either biomarker alone (Table 2). Adding the next top-ranked biomarker resulted in decreasing specificity, but the specificity of all panels containing from 2 to 7 of the top-ranked biomarkers was higher than that for the individual biomarkers included, except for IL-6. When applying TB risk cut-off points obtained from the full dataset, sensitivity remained high ( $>85\%$ ) for all biomarker panels among sputum smear-negative TB patients (Table 3).

### Discussion

A simple, low-cost, and accurate TB screening test is a key priority for achieving global TB elimination targets. In this study, we analyzed 44 blood biomarkers and identified at least five

**Table 1. Variable importance and median concentrations (pg/ml) of 7 selected biomarkers (N = 262).**

Biomarker	Variable Importance Ranking	No TB (n = 107)	TB (n = 155)	Fold Difference	p-value
		Median (IQR)	Median (IQR)		
IFN- $\gamma$	1	20 (11–34)	61 (36–126)	3.1	<0.001
IL-6	2	23 (13–50)	77 (40–130)	3.3	<0.001
MIG	3	2994 (1508–6425)	7741 (3346–13495)	2.6	<0.001
IL-18	4	248 (137–438)	482 (272–817)	1.9	<0.001
CRP (mg/l)	5	69 (23–158)	140 (78–209)	2.0	<0.001
MDC	6	788 (532–1169)	673 (518–925)	0.9	0.064
GRO	7	1390 (963–1931)	1432 (1111–1858)	1.0	0.738

Abbreviations: TB, tuberculosis; IQR, interquartile range, INF- $\gamma$ , Interferon gamma; IL-6, Interleukin-6; MIG, Monokine induced by interferon- $\gamma$ ; IL-18, Interleukin-18; CRP, C-reactive protein; MDC, Macrophage-derived chemokine; GRO, Growth-related oncogene.

<https://doi.org/10.1371/journal.pone.0206119.t001>



**Table 2. Accuracy of biomarker panels with sensitivity constrained to 90% (N = 262).**

Biomarker Panel	Specificity (95% CI)	cvAUC
IFN- $\gamma$ , IL-6	50.4 (46.7–53.3)	0.844
IFN- $\gamma$ , IL-6, MIG	48.3 (44.9–51.4)	0.830
IFN- $\gamma$ , IL-6, MIG, IL-18	46.6 (43.0–49.5)	0.851
IFN- $\gamma$ , IL-6, MIG, IL-18, CRP	40.3 (36.4–43.0)	0.825
IFN- $\gamma$ , IL-6, MIG, IL-18, CRP, GRO	41.8 (37.4–45.8)	0.826
IFN- $\gamma$ , IL-6, MIG, IL-18, CRP, GRO, MDC	40.3 (36.4–43.9)	0.836

Abbreviations: TB, tuberculosis; CI, confidence interval; cvAUC, cross-validated area under the receiver operator curve; INF- $\gamma$ , Interferon gamma; IL-6, Interleukin-6; MIG, Monokine induced by interferon- $\gamma$ ; IL-18, Interleukin-18; CRP, C-reactive protein; MDC, Macrophage-derived chemokine; GRO, Growth-related oncogene.

<https://doi.org/10.1371/journal.pone.0206119.t002>

(IFN- $\gamma$ , IL-6, MIG, IL-18, and CRP) that showed potential for utility in TB screening. All five biomarkers had levels that were >1.5-fold higher in TB patients than in patients without TB in the pilot and full datasets, and were the top-ranked biomarkers by variable importance in the full dataset. With sensitivity constrained to  $\geq 90\%$ , specificity was poor—as expected in an inpatient cohort—for all individual biomarkers and for all biomarker panels. However, specificity was higher for biomarker panels than for individual biomarkers, including CRP. Combinations of the biomarkers identified here should be further evaluated among ambulatory PLHIV undergoing systematic screening for active TB.

Our data are consistent with previous studies that have evaluated blood biomarkers in the context of TB diagnosis. Levels of IFN- $\gamma$ , IL-6, MIG, and IL-18 have all been found to be higher in patients with TB than in healthy controls [21], household contacts [23], or patients undergoing TB evaluation who test negative [24, 26]. CRP has been more extensively evaluated. Sensitivity has been consistently high while specificity has varied with the population being studied (range 6–52% in inpatient studies and 58–81% in ambulatory screening studies [31]). Our study is among the first to evaluate all five of these biomarkers, and the previous studies support that the biomarkers identified here can be expected to have higher specificity in the context of TB screening in ambulatory settings, where patients without TB are less likely to have other illnesses resulting in systemic inflammation.

In addition to the biomarkers identified here, others such as IP-10 have been reported recently to have utility for differentiating patients with and without active TB. For example,

**Table 3. Sensitivity of biomarker panels among sputum smear-positive vs. smear-negative TB patients.**

Biomarker Panel	Sensitivity (95% CI)	
	Smear-positive TB (N = 50)	Smear-negative TB (N = 105)
IFN- $\gamma$ , IL-6	91.3 (89.5–92.4)	85.7 (84.0–86.0)
IFN- $\gamma$ , IL-6, MIG	91.7 (89.5–93.3)	85.5 (84.0–86.0)
IFN- $\gamma$ , IL-6, MIG, IL-18	90.8 (89.5–92.4)	87.5 (84.0–92.0)
IFN- $\gamma$ , IL-6, MIG, IL-18, CRP	91.5 (89.5–93.3)	88.2 (84.0–92.1)
IFN- $\gamma$ , IL-6, MIG, IL-18, CRP, GRO	90.8 (89.5–92.4)	88.3 (82.0–94.0)
IFN- $\gamma$ , IL-6, MIG, IL-18, CRP, GRO, MDC	91.1 (89.5–92.4)	88.1 (82.0–94.0)

Abbreviations: TB, tuberculosis; CI, confidence interval; INF- $\gamma$ , Interferon gamma; IL-6, Interleukin-6; MIG, Monokine induced by interferon- $\gamma$ ; IL-18, Interleukin-18; CRP, C-reactive protein; MDC, Macrophage-derived chemokine; GRO, Growth-related oncogene.

<https://doi.org/10.1371/journal.pone.0206119.t003>

Biraro et al found that IP-10 was able to differentiate patients with latent or active TB versus those who were not infected [25] and Mihret et al found that IP-10 plasma levels could differentiate between active TB patients and healthy household contacts [23]. Our study confirmed these findings; however, we replaced IP-10 with MIG for analyses (See Biomarker Selection). Due to the strong performance of IP-10 in our data and prior literature, it should be included along with IFN- $\gamma$ , IL-6, MIG, IL-18, and CRP in future studies of TB screening in ambulatory populations.

Our study has several strengths, including a rigorous TB reference standard, robust statistical methods, and the use of unstimulated peripheral blood specimens in contrast to many biomarker studies that use stimulated specimens. However, the study also has several limitations. First, the study population was not representative of the majority of patients who would undergo TB screening due to the higher severity of illness and thus greater systemic inflammation in the TB-negative patients in this cohort. However, we successfully identified a smaller number of biomarkers that can be further evaluated in future studies for TB screening in out-patient settings. Second, samples from many patients were not included because TB status could not be clearly defined. Additionally, patients who could not produce sputum were excluded as their TB status could not be classified. However, symptoms and severity of illness were similar among patients included and excluded from the analysis. Nonetheless, the large number of exclusions introduces the potential for bias. Third, the plasma samples used in this analysis had been stored for >2 years and some cytokines/chemokines could have degraded more than others [41]. Last, even if validated in a screening cohort, point-of-care testing platforms would need to be developed before panels of inflammatory markers could be used for TB screening by frontline health workers in high-burden countries.

## Conclusions

Direct measurement of a panel of inflammatory markers, cytokines, and chemokines in peripheral blood is a promising approach to TB screening. Each of the biomarkers identified in this study performed better than symptom-based screening, and performed better than CRP alone when combined into panels. These biomarkers should be further evaluated in out-patient settings where most TB screening occurs and where other illnesses associated with systemic inflammation are less common in order to identify the optimal panel and to determine whether sensitivity and specificity meet targets established by the WHO for a TB screening test.

## Supporting information

**S1 Table. Median biomarker levels (pg/ml), N = 74.**  
(DOCX)

**S2 Table. Variable importance of biomarkers, in rank order (N = 74).**  
(DOCX)

**S3 Table. Diagnostic accuracy of individual top-ranked biomarkers with sensitivity constrained to  $\geq 90\%$  (N = 262).**  
(DOCX)

**S1 File. Initial and repeat values of cytokines with mean, standard deviation, and coefficient of variation.**  
(XLS)

## Acknowledgments

We would like to thank the patients, staff, and administration of Mulago Hospital for enabling this study to be completed.

## Author Contributions

**Conceptualization:** Resmi Ravindran, Luke Strnad, Imran H. Khan, Adithya Cattamanchi.

**Data curation:** Katherine Farr, Resmi Ravindran, Luke Strnad, Emily Chang, Lelia H. Chaisson, Imran H. Khan, Adithya Cattamanchi.

**Formal analysis:** Katherine Farr, Resmi Ravindran, Luke Strnad, Emily Chang, Imran H. Khan, Adithya Cattamanchi.

**Funding acquisition:** Laurence Huang, Adithya Cattamanchi.

**Investigation:** Katherine Farr, Resmi Ravindran, William Worodria, Alfred Andama, Irene Ayakaka, Priscilla Bbosa Nalwanga, Patrick Byanyima, Nelson Kalema, Sylvia Kaswabuli, Wincelous Katagira, Kyomugisha Denise Aman, Emmanuel Musisi, Nuwagaba Wallen Tumwine, Ingvar Sanyu, Robert Ssebunya.

**Methodology:** Katherine Farr, Resmi Ravindran, Imran H. Khan, Adithya Cattamanchi.

**Project administration:** Katherine Farr, Resmi Ravindran.

**Supervision:** J. Lucian Davis, Laurence Huang, Imran H. Khan, Adithya Cattamanchi.

**Visualization:** Katherine Farr, Resmi Ravindran, Luke Strnad, Emily Chang.

**Writing – original draft:** Katherine Farr, Resmi Ravindran, Luke Strnad, Imran H. Khan, Adithya Cattamanchi.

**Writing – review & editing:** Katherine Farr, Resmi Ravindran, Luke Strnad, Emily Chang, Lelia H. Chaisson, Christina Yoon, William Worodria, Alfred Andama, Irene Ayakaka, Priscilla Bbosa Nalwanga, Patrick Byanyima, Nelson Kalema, Sylvia Kaswabuli, Wincelous Katagira, Kyomugisha Denise Aman, Emmanuel Musisi, Nuwagaba Wallen Tumwine, Ingvar Sanyu, Robert Ssebunya, J. Lucian Davis, Laurence Huang, Imran H. Khan, Adithya Cattamanchi.

## References

1. World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization; 2016.
2. United Nations Joint Programme on HIV/AIDS. Global AIDS update—2016. Geneva: UNAIDS; 2016.
3. World Health Organization. Intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: WHO Press; 2008.
4. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO Press; 2011.
5. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. *PLoS Med.* 2011; 8(1):e1000391. <https://doi.org/10.1371/journal.pmed.1000391> PMID: 21267059
6. World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. Geneva: WHO Press; 2013.
7. Lemaire JF, Casenghi M. New diagnostics for tuberculosis: fulfilling patient needs first. *J Int AIDS Soc.* 2010; 13:40. <https://doi.org/10.1186/1758-2652-13-40> PMID: 20973946
8. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening

- before antiretroviral therapy. *Clin Infect Dis*. 2012; 54(8):1071–9. <https://doi.org/10.1093/cid/cir1039> PMID: 22318975
9. Kufa T, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, Grant AD, et al. Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. *J Acquir Immune Defic Syndr*. 2012; 60(2):e22–8. <https://doi.org/10.1097/QAI.0b013e318251ae0b> PMID: 22627184
  10. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. *Int J Tuberc Lung Dis*. 2013; 17(5):636–43. <https://doi.org/10.5588/ijtld.12.0811> PMID: 23575330
  11. Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, et al. Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. *Int J Tuberc Lung Dis*. 2013; 17(4):532–9. <https://doi.org/10.5588/ijtld.12.0737> PMID: 23485388
  12. Rangaka MX, Wilkinson RJ, Glynn JR, Boule A, van Cutsem G, Goliath R, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. *Clin Infect Dis*. 2012; 55(12):1698–706. <https://doi.org/10.1093/cid/cis775> PMID: 22955441
  13. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. *Int J Tuberc Lung Dis*. 2006; 10(5):523–9. PMID: 16704034
  14. Telisinghe L, Fielding KL, Malden JL, Hanifa Y, Churchyard GJ, Grant AD, et al. High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. *PLoS One*. 2014; 9(1):e87262. <https://doi.org/10.1371/journal.pone.0087262> PMID: 24498059
  15. van't Hoog AH, Langendam M, Mitchell E, Cobelens FG, Sinclair D, Leeflang MMG, et al. A systematic review of the sensitivity and specificity of symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative persons and persons with unknown HIV status. Geneva: WHO Press; 2013.
  16. Dawson R, Masuka P, Edwards DJ, Bateman ED, Bekker LG, Wood R, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. *Int J Tuberc Lung Dis*. 2010; 14(1):52–8. PMID: 20003695
  17. Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. *Nature*. 2006; 444 Suppl 1:49–57.
  18. Batz H-G, Cooke GS, Reid SD. Towards lab-free tuberculosis diagnosis. Geneva: Stop TB Partnership. 2011.
  19. Yu Y, Zhang Y, Hu S, Jin D, Chen X, Jin Q, et al. Different patterns of cytokines and chemokines combined with IFN-gamma production reflect Mycobacterium tuberculosis infection and disease. *PLoS One*. 2012; 7(9):e44944. <https://doi.org/10.1371/journal.pone.0044944> PMID: 23028695
  20. Tebruegge M, Dutta B, Donath S, Ritz N, Forbes B, Camacho-Badilla K, et al. Mycobacteria-Specific Cytokine Responses Detect Tuberculosis Infection and Distinguish Latent from Active Tuberculosis. *Am J Respir Crit Care Med*. 2015; 192(4):485–99. <https://doi.org/10.1164/rccm.201501-0059OC> PMID: 26030187
  21. Ravindran R, Krishnan VV, Khanum A, Luciw PA, Khan IH. Exploratory study on plasma immunomodulator and antibody profiles in tuberculosis patients. *Clin Vaccine Immunol*. 2013; 20(8):1283–90. <https://doi.org/10.1128/CVI.00213-13> PMID: 23761664
  22. Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, et al. Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. *J Acquir Immune Defic Syndr*. 2014; 65(5):551–6. <https://doi.org/10.1097/QAI.000000000000085> PMID: 24346636
  23. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R, et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. *J Infect*. 2013; 66(4):357–65. <https://doi.org/10.1016/j.jinf.2012.11.005> PMID: 23178506
  24. Chung W, Lee K, Jung Y, Kim Y, Park J, Sheen S, et al. Serum CXCR3 ligands as biomarkers for the diagnosis and treatment monitoring of tuberculosis. *Int J Tuberc Lung Dis*. 2015; 19(12):1476–84. <https://doi.org/10.5588/ijtld.15.0325> PMID: 26614189
  25. Biraro IA, Kimuda S, Egesa M, Cose S, Webb EL, Joloba M, et al. The use of interferon gamma inducible protein 10 as a potential biomarker in the diagnosis of latent tuberculosis infection in Uganda. *PLoS One*. 2016; 11(1):e0146098. <https://doi.org/10.1371/journal.pone.0146098> PMID: 26771653
  26. Chen T, Li Z, Yu L, Li H, Lin J, Guo H, et al. Profiling the human immune response to Mycobacterium tuberculosis by human cytokine array. *Tuberculosis (Edinb)*. 2016; 97:108–17.
  27. Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho SN, et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. *Int J Infect Dis*. 2012; 16(12):e855–9. <https://doi.org/10.1016/j.ijid.2012.07.013> PMID: 22959355

28. Wilson D, Badri M, Maartens G. Performance of serum C-reactive protein as a screening test for smear-negative tuberculosis in an ambulatory high HIV prevalence population. *PloS One*. 2011; 6(1): e15248. <https://doi.org/10.1371/journal.pone.0015248> PMID: 21249220
29. Drain PK, Mayeza L, Bartman P, Hurtado R, Moodley P, Varghese S, et al. Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa. *Int J Tuberc Lung Dis*. 2014; 18(1):20–6. PMID: 24505819
30. Yoon C, Semitala FC, Atuhumuza E, Katende J, Mwebe S, Asege L, et al. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. *Lancet Infect Dis*. 2017; 17(12):1285–92. [https://doi.org/10.1016/S1473-3099\(17\)30488-7](https://doi.org/10.1016/S1473-3099(17)30488-7) PMID: 28847636
31. Yoon C, Chaisson LH, Patel SM, Allen IE, Drain PK, Wilson D, et al. Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis. *Int J Tuberc Lung Dis*. 2017; 21(9):1013–9. <https://doi.org/10.5588/ijtld.17.0078> PMID: 28826451
32. Cattamanchi A, Davis JL, Worodria W, den Boon S, Yoo S, Matovu J, et al. Sensitivity and specificity of fluorescence microscopy for diagnosing pulmonary tuberculosis in a high HIV prevalence setting. *Int J Tuberc Lung Dis*. 2009; 13(9):1130–6. PMID: 19723403
33. Cattamanchi A, Huang L, Worodria W, den Boon S, Kalema N, Katagira W, et al. Integrated strategies to optimize sputum smear microscopy: a prospective observational study. *Am J Respir Crit Care Med*. 2011; 183(4):547–51. <https://doi.org/10.1164/rccm.201008-1207OC> PMID: 20851925
34. Archer KJ, Kimes RV. Empirical characterization of random forest variable importance measures. *Comput Stat Data Anal*. 2008; 52:2249–60.
35. Strobl C, Boulesteix AL, Augustin T. Unbiased split selection for classification trees based on the Gini Index. *Comput Stat Data Anal*. 2007; 52:483–501.
36. Polley EC, Van der Laan MJ. Super learner in prediction. University of California Berkeley Division of Biostatistics Working Paper Series. 2010; Working Paper 266.
37. Hubbard A, Munoz ID, Decker A, Holcomb JB, Schreiber MA, Bulger EM, et al. Time-dependent prediction and evaluation of variable importance using superlearning in high-dimensional clinical data. *J Trauma Acute Care Surg*. 2013; 75(1 Suppl 1):S53–60.
38. Gelman A, Jakulin A, Pittau MG, Su YS. A weakly informative default prior distribution for logistic and other regression models. *Ann Appl Stat*. 2008:1360–83.
39. Hastie T, Tibshirani R, Friedman J. *The elements of statistical learning: data mining, inference, and prediction*. 2nd ed. Springer series in statistics. New York: Springer; 2009.
40. van der Laan MJ, Rose S. *Targeted learning: causal inference for observational and experimental data*. New York: Springer Science & Business Media; 2011.
41. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. *BMC Immunol*. 2009; 10:52. <https://doi.org/10.1186/1471-2172-10-52> PMID: 19785746